An actual-to-expected ratio compares the number of deaths that actually occurred in a group of insured lives against the number a mortality table predicted, expressed as a percentage. A ratio of 100 percent means the prediction matched reality. Above 100 percent means more people died than expected, so the life expectancy estimates were too long. Below 100 percent means people outlived the estimates.
It is a scorecard for the firms that produce life expectancy reports, and it is the single most important number in the life settlement market that no consumer is ever shown. Understanding why it exists explains something that otherwise looks like incompetence: why two life expectancy reports on the same person, ordered in the same month, can differ by four years, and why an offer that was strong in one year is weak in the next.
The short answer is that a life expectancy estimate is a forecast, forecasts get graded, and when the grades come in badly the whole market reprices at once. That has happened, on a large scale, within living memory. Figures and dates below are stated as of 2026; confirm current mortality table vintages and underwriter practices with your broker in writing. Pine Lake Legacy provides education and a free policy review only.
In This Article
The Problem the Ratio Was Built to Solve
A buyer of a life insurance policy in the secondary market is pricing a bond with an unknown maturity date. The purchase price, the premiums that must be paid until maturity, and the return all depend on one estimate: how long the insured will live. That estimate comes from a life expectancy underwriter, which reviews the medical records, applies a mortality multiplier to a base table, and produces a median life expectancy in months.
Nothing about that process is self-checking. An underwriter could issue systematically optimistic estimates for years and nobody would know from any individual case, because any one person’s death date tells you nothing about the quality of a forecast. Only the aggregate does. Run the estimates forward across thousands of lives, count the deaths that actually occurred, divide by the deaths the table predicted, and you have a number that says whether the underwriter is calibrated.
That is the actual-to-expected ratio, and it is used the same way in the insurance industry generally — carriers compute A/E ratios against valuation tables to test their own mortality assumptions. In the settlement market it became the currency by which institutional buyers judged which underwriter’s reports to trust and how much to discount them.
The base tables themselves come mainly from the Society of Actuaries’ Valuation Basic Table series, with the 2008 and 2015 vintages the ones most often referenced in this market. Which table an underwriter uses, and what multiplier it applies, are both legitimate questions to ask. See how the VBT tables work.
The 2008 Recalibration and Why the Market Still Talks About It
The reason the A/E ratio is not an academic topic is what happened in 2008. Through the mid-2000s, institutional investors bought life settlement portfolios priced on life expectancy estimates from a small number of underwriting firms. Actual deaths began running below expectations — insureds were living longer than the reports said. The A/E ratios were coming in low.
In 2008, major life expectancy underwriters revised their methodologies and lengthened their estimates materially. Contemporaneous industry accounts described extensions on the order of roughly 20 to 25 percent for affected cohorts. A longer life expectancy means more premiums to pay and a later payout, which means a lower present value. Portfolios purchased on the old estimates were suddenly worth substantially less, and investors took significant write-downs.
The consequences reshaped the market. Buyers began ordering two or more life expectancy reports and blending them. Pricing became more conservative across the board. Some capital left and did not return. And the market developed an institutional memory that shows up in offers to this day: a policy on a healthy 72-year-old, where the life expectancy estimate carries the most uncertainty, is priced cautiously precisely because of what caution was worth in 2008.
This is why a seller should never treat a life expectancy report as a medical opinion about how long they will live. It is a pricing input produced by a firm being graded on its aggregate record, and its incentives run toward whichever direction its last A/E report suggested it had erred.
| A/E Ratio | What Happened | What It Says About the Estimates | Effect on Pricing |
|---|---|---|---|
| Above 100% | More deaths than predicted | Life expectancies were too long | Tends to depress offers on similar files |
| About 100% | Deaths matched the table | The underwriter is calibrated | Neutral |
| Below 100% | Fewer deaths than predicted | Life expectancies were too short | Prompts recalibration and lower offers, as in 2008 |
How to Read the Number Without Getting It Backwards
The direction confuses almost everyone, so fix it with an example. Take 1,000 insured lives and a mortality table predicting 40 deaths in a year.
If 48 deaths actually occur, the A/E ratio is 120 percent. More people died than predicted, so the underwriter’s life expectancies were too long and its estimates were conservative. For a policy seller, an underwriter running above 100 percent is producing estimates that understate how quickly the cohort is dying, which tends to depress offers.
If 32 deaths occur, the ratio is 80 percent. Fewer died than predicted, so the estimates were too short and too aggressive. That is the 2008 pattern, and it is the direction that costs investors money.
Two cautions on interpretation. A/E ratios are only meaningful over large samples and long observation windows; a ratio computed on 200 lives over two years is noise. And ratios are computed on a defined cohort — by age band, by impairment category, by report vintage — so a single headline number for a firm can conceal that it is well calibrated on one population and badly calibrated on another.
Note also what the ratio is not: it is not a statement about any individual. A person whose report says 96 months may die in 20 months or live 240. The median in a life expectancy report is exactly that, a median, and roughly half of a comparable cohort outlives it. Our page on what happens when someone outlives the estimate covers that reality directly.
Four Terms It Is Confused With
The mortality multiplier, or debit rating. This applies to one insured, not to a firm. An underwriter reviewing a person’s records may conclude their mortality risk is 250 percent of a standard life of the same age and sex, and applies that multiplier to the base table to derive the life expectancy. A multiplier describes a person; an A/E ratio describes an underwriter’s track record.
The life expectancy itself. Usually quoted as a median in months. It is the output; the A/E ratio is the audit of the outputs. Our page on what a life expectancy report contains covers the document a seller may actually see.
The valuation table. The Society of Actuaries’ VBT tables are the reference mortality curves. They are inputs to the estimate, not measures of accuracy, and different vintages produce different answers from the same medical file.
Internal rate of return. The buyer’s required return on the transaction, which drives the offer price alongside the life expectancy. Two buyers with identical life expectancy estimates can bid very differently because their return targets differ. This is why soliciting multiple providers matters more than arguing about the life expectancy.
See how life expectancy underwriting works for how these pieces fit together in a single file.
What a Seller Should Actually Do With This
You will not be shown an A/E ratio and you should not chase one. What this knowledge gives you is the right set of questions and the right expectations.
Ask your broker, in writing: which life expectancy firms produced reports on my file, how many reports were ordered, and are the offers based on a single report or a blend. Two reports differing by three or more years is normal, not evidence of an error, and knowing that in advance prevents a household from concluding the process is rigged.
Ask whether a report can be re-ordered. Life expectancy reports have a shelf life — most buyers want one within roughly 12 months — and a material change in health since the last report is a legitimate reason to obtain a fresh one. A seller whose condition has worsened materially since an earlier report should raise it rather than accept a stale estimate.
Understand what moves an offer and what does not. Health and age move it. Premium load moves it. The number of buyers who competed for the file moves it. The carrier’s brand does not. Your negotiating skill barely does. This is why the practical advice is always the same: get multiple providers to bid, insist on the bid history in writing, and treat the life expectancy estimate as a pricing input rather than a verdict.
And keep the honest baseline in view: for many households the right answer is not to sell at all. Small face amounts, insureds in good health for their age, coverage a survivor still needs, and policies with an unused accelerated death benefit rider all point the other way. To find out which case yours is, send the policy cover page and the most recent annual statement for a free, no-obligation review, or call (732) 978-9575. Pine Lake Legacy does not purchase policies; tax questions belong with your CPA and benefits questions with your state agency or a SHIP counselor.
Frequently Asked Questions
Will I ever see an A/E ratio for my own policy?
No. It is an aggregate statistic about an underwriting firm’s track record across thousands of lives, not a number attached to any individual file. What you may see is the life expectancy report itself. Ask your broker which firms produced reports on your file and whether the offers reflect one report or a blend.
Why do two life expectancy reports on the same person differ so much?
Different firms use different base mortality tables, different vintages, and different methods for translating medical impairments into a mortality multiplier. Differences of three years or more are routine, not evidence of error. Buyers commonly blend multiple reports for exactly this reason.
What happened in 2008?
Actual deaths in settlement portfolios ran below what the life expectancy estimates predicted, and major underwriters responded by lengthening their estimates materially, with contemporaneous accounts describing extensions on the order of 20 to 25 percent for affected cohorts. Portfolio values fell and the market repriced. Pricing has remained more conservative since.
Does a longer life expectancy mean a lower offer?
Generally yes. A longer estimate means more premiums to pay before the death benefit is collected and a later payout, both of which reduce present value. That is why a documented deterioration in health since an earlier report is worth raising with your broker and may justify ordering a fresh report.
How old can a life expectancy report be before buyers reject it?
Most buyers want a report produced within roughly the last twelve months, though practice varies by provider and by case. If your report is older or your condition has changed materially, ask your broker whether a new report should be ordered before offers are solicited.
Can I choose which life expectancy firm evaluates me?
Usually not. The provider or broker selects the firms and pays for the reports. What you can do is ask which firms were used, how many reports were ordered, and how the offers relate to them. Getting several providers to compete matters more to your outcome than the identity of the underwriter.
Find out what your policy is worth — free, confidential, no obligation.
A 15-minute educational review covers your eligibility, every alternative, and a realistic view of what each path would net you.
Related Reading
- What Is The Vbt Mortality Table
- What Is A Life Expectancy Report
- What Is Life Expectancy Underwriting
- What Is A Life Expectancy Provider
- Living Longer Than The Life Expectancy Report
- How Much Is My Policy Worth
- What Is A Life Settlement Broker
- When A Life Settlement Is A Bad Idea
Pine Lake Legacy does not purchase life insurance policies and does not provide legal, tax, or investment advice. Information provided is for educational purposes only. Eligibility for any option, including life settlements, is not guaranteed and depends on individual circumstances, policy terms, underwriting, and market conditions. Consult independent legal, tax, or financial professionals before making decisions regarding a life insurance policy.